MedTrace Logo

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153

NCT02517359 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-03-04

No results posted yet for this study

Summary

RV6153 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).

The main purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat doses of RV6153

Conditions

Interventions

DRUG

RV6153 single dose

Safety and tolerability of single doses

DRUG

RV6153 matching placebo single dose

Safety and tolerability of single doses

DRUG

RV6153 14 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV6153 matching placebo 14 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV6153 28 day repeat dose

Safety and tolerability of repeat doses

DRUG

RV6153 matching placebo 28 day repeat dose

Safety and tolerability of repeat doses

Sponsors & Collaborators

  • Respivert Ltd

    lead INDUSTRY

Principal Investigators

  • Christopher O'Brien, MD, PhD, FCCP · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02517359 on ClinicalTrials.gov